Cargando…

Characteristics and Effect of Rivaroxaban on Venous Thromboembolism in Korean Patients Compared to Western Population: A Subgroup Analysis from XALIA(-LEA) Study

PURPOSE: This study aimed to compare the characteristics of venous thromboembolic disease (VTE) in Korean to Caucasian population. MATERIALS AND METHODS: XALIA-LEA and XALIA were phase IV non-interventional prospective studies with identical designs that investigated the effect of rivaroxaban versus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Min, Seung-Kee, Kim, Ji-Sun, Kim, Jang Yong, Park, Ui Jun, Lee, Taehoon, Kang, Jin Mo, Park, Sun Cheol, Choi, Won-Il, Park, Ki-Hyuk, Gebel, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society for Vascular Surgery 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794492/ https://www.ncbi.nlm.nih.gov/pubmed/36573027 http://dx.doi.org/10.5758/vsi.220039

Ejemplares similares

Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA‐LEA noninterventional studies
por: Haas, Sylvia, et al.
Publicado: (2021)

Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE
por: Ageno, Walter, et al.
Publicado: (2017)

Patient-Reported Treatment Experience with Oral Rivaroxaban: Results from the Noninterventional XALIA Study of Deep-Vein Thrombosis
por: Cano, Stefan, et al.
Publicado: (2018)

Rivaroxaban and Acetylsalicylic Acid for Prevention of Venous Thromboembolism Following Total Knee Arthroplasty in Korean Patients
por: Chung, Kyu Sung, et al.
Publicado: (2018)

Predictive value of venous thromboembolism (VTE)‐BLEED to predict major bleeding and other adverse events in a practice‐based cohort of patients with VTE: results of the XALIA study
por: Klok, Frederikus A., et al.
Publicado: (2018)

Rivaroxaban for cancer-associated venous thromboembolism
por: Liang, Bo, et al.
Publicado: (2021)

Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism
por: Bistervels, Ingrid M., et al.
Publicado: (2022)

Fatigue after initiating rivaroxaban for venous thromboembolism
por: Karlsvik, Tina Margrethe, et al.
Publicado: (2020)

Korean Guidelines for the Prevention of Venous Thromboembolism
por: Bang, Soo-Mee, et al.
Publicado: (2010)

Thrombophilia in Korean patients with arterial or venous thromboembolisms
por: Kim, Sungbae, et al.
Publicado: (2016)

Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
por: Bauersachs, Rupert, et al.
Publicado: (2020)

Rivaroxaban in acute venous thromboembolism: UK prescribing experience
por: Speed, Victoria, et al.
Publicado: (2021)

XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis
por: Ageno, Walter, et al.
Publicado: (2014)

Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy
por: Wells, Philip S, et al.
Publicado: (2014)

Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism
por: Harder, Sebastian
Publicado: (2014)

Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2018)

Rivaroxaban vs. warfarin for the treatment and prevention of venous thromboembolism: A meta-analysis
por: Liu, Zhuang, et al.
Publicado: (2023)

The incidence of venous thromboembolism is not lowin Korean patients with advanced pancreatic cancer
por: Yoon, Seug Yun, et al.
Publicado: (2018)

Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism
por: Berger, Jeffrey S., et al.
Publicado: (2017)

Treatment with rivaroxaban and monitoring of coagulation profiles in two dogs with venous thromboembolism
por: UCHIDA, Mona, et al.
Publicado: (2020)

Adherence to rivaroxaban for the treatment of venous thromboembolism–Results from the FIRST registry
por: Speed, Victoria, et al.
Publicado: (2021)

Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial
por: Yhim, Ho-Young, et al.
Publicado: (2019)

The Risk of Venous Thromboembolism in Korean Patients with Breast Cancer: A Single-Center Experience
por: Park, Jung Ho, et al.
Publicado: (2023)

Rivaroxaban after Thrombolysis in Acute Iliofemoral Venous Thrombosis: A Randomized, Open-labeled, Multicenter Trial
por: Kang, Jin Mo, et al.
Publicado: (2019)

New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban
por: Borris, Lars Carl
Publicado: (2008)

Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery
por: Du, Wei, et al.
Publicado: (2015)

Use of rivaroxaban in sickle cell disease and venous thromboembolism: A case report
por: Rozi, Waail, et al.
Publicado: (2021)

Variation in Plasma Levels of Apixaban and Rivaroxaban in Clinical Routine Treatment of Venous Thromboembolism
por: Reda, Sara, et al.
Publicado: (2022)

Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J’xactly study
por: Migita, Shohei, et al.
Publicado: (2023)

Patient Management Strategies and Long-Term Outcomes in Isolated Distal Deep-Vein Thrombosis versus Proximal Deep-Vein Thrombosis: Findings from XALIA
por: Ageno, Walter, et al.
Publicado: (2019)

The prevalence and clinical manifestation of hereditary thrombophilia in Korean patients with unprovoked venous thromboembolisms
por: Lee, Su Yeon, et al.
Publicado: (2017)

Venous thromboembolism prophylaxis after total knee arthroplasty (TKA): aspirin vs. rivaroxaban()
por: Colleoni, Jose Luiz, et al.
Publicado: (2017)

Rivaroxaban for the treatment of venous thromboembolism in real life: A single-center prospective study
por: Demelo-Rodríguez, Pablo, et al.
Publicado: (2019)

Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer
por: Lee, Jang Ho, et al.
Publicado: (2019)

Rivaroxaban for cancer-associated venous thromboembolism: A systematic review and meta-analysis protocol
por: Liang, Bo, et al.
Publicado: (2019)

Oral Rivaroxaban Versus Standard Therapy in Acute Venous Thromboembolism Treatment for Vietnamese Patients
por: Bui, My Hanh, et al.
Publicado: (2019)

Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers
por: Lee, Jang Ho, et al.
Publicado: (2019)

Validation of venous thromboembolism diagnoses in patients receiving rivaroxaban or warfarin in The Health Improvement Network
por: Ruigómez, Ana, et al.
Publicado: (2020)

Rivaroxaban Treatment for Patients With Unprovoked or Provoked Venous Thromboembolism　― Subanalysis of the J’xactly Study ―
por: Hisatake, Shinji, et al.
Publicado: (2022)

Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran
por: Al-Ghafry, Maha, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_llavteach3vcij7inqed26ha0t